| Original language | English |
|---|---|
| Pages (from-to) | 587-589 |
| Number of pages | 3 |
| Journal | American Journal of Clinical Dermatology |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American Journal of Clinical Dermatology, Vol. 23, No. 4, 07.2022, p. 587-589.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Oncodermatology
T2 - Advancing the Science and Care of Cancer Patients and Survivors
AU - Bang, Alexander S.
AU - Anadkat, Milan J.
AU - Choi, Jennifer N.
AU - LeBoeuf, Nicole R.
AU - Jung, Jae Y.
AU - Markova, Alina
AU - Gordon, Allison
AU - Rossi, Anthony M.
AU - Noor, Sarah J.
AU - Sibaud, Vincent
AU - Lacouture, Mario E.
N1 - Funding Information: Dr. Anadkat has served as a consultant for ImClone, Bristol Myers Squibb, AstraZeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli Lilly, Abbvie, Boehringer-Ingelheim, Innovaderm, UCB Biopharma, Novocure, OnQuality, and Springworks. Dr. Anadkat has served as a Principal Investigator for Novartis, Boehringer-Ingelheim, Lutris, OnQuality, UCB Biopharma, InflamRx, Eli Lilly, InCyte, Abbvie, AnaptysBio, Hana Biosciences, Xoma, Veloce, Biogen, Xbiotech, and Chemocentryx. Dr. Choi has a consultant role with OnQuality, Regeneron, Parexel, Azitra, La Roche-Posay Pharmaceuticals, and PraHealthSciences. Dr. Choi has served as a consultant for Biotest AG, Keratin Biosciences, Bristol Meyers Squibb, Novartis, Array Biopharma, and Kyowa Kirin International. Dr. Choi has served as a Principal Investigator for OnQuality, InCyte, and Veloce. Dr. Jung has a consultant role at Regeneron and Sanofi. Dr. Lacouture has a consultant role with Oncoderm Labs, Johnson and Johnson, Novocure, QED, Bicara, Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, AstraZeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Azitra, Roche, Oncoderm, NCODA, and Apricity. Dr. Lacouture also receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis, National Institutes of Health, and AstraZeneca. Dr. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics. Dr. Markova has a consultant role with Alira Health and Blueprint Medicines, and receives research funding from Amryt Pharma and Incyte Corp. Dr. Noor has a consultant role with Kyowa Kirin. Dr. Sibaud has received consulting fees from Amgen, Bristol Myers Squibb, Pierre Fabre, and Bayer. Dr. Sibaud has received honoraria for lectures from Bristol Myers Squibb, Pierre Fabre, Novartis, and Incyte. Dr. Sibaud participates on a data safety monitoring board for Bristol Myers Squibb. Dr. Rossi has served as a consultant for Almirall, Mavig, Dynamed, Canfield Scientific, Allergan Inc., Biofrontera, MD, Lam Therapeutics, Regeneron, Cutera, Skinfix, and L’Oreal. Dr. Rossi has received research funding from Regen, LeoPharma, and Biofrontera. Dr. Rossi serves on the editorial boards for Lasers in Surgery and Medicine, Cutis, Journal of the American Academy of Dermatology, and Dermatologic Surgery. Alexander Bang and Dr. Gordon have no conflicts of interest that might be directly relevant to the contents of this letter.
PY - 2022/7
Y1 - 2022/7
UR - http://www.scopus.com/inward/record.url?scp=85133523209&partnerID=8YFLogxK
U2 - 10.1007/s40257-022-00705-z
DO - 10.1007/s40257-022-00705-z
M3 - Letter
C2 - 35788536
AN - SCOPUS:85133523209
SN - 1175-0561
VL - 23
SP - 587
EP - 589
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
IS - 4
ER -